financetom
Business
financetom
/
Business
/
UltraTech Cement's profit and margin shrink as raw material costs spike
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UltraTech Cement's profit and margin shrink as raw material costs spike
Oct 19, 2022 5:54 AM

UltraTech Cement reported its quarterly financial results for the July to September period in which its profit declined over 42 percent compared to the same quarter last year to Rs 759 crore, the company said in an exchange filing on Wednesday.

However, the cement maker's profit slightly exceeded estimates of a CNBC-TV18 poll of analysts who had pegged the figure at Rs 727 crore for the September quarter.

UltraTech Cement's revenue too beat projections and came in at Rs 13,893 crore, up 15.6 percent from Rs 12,016 crore in the same quarter in the previous financial year. The topline is better than expected on the back of better realisations.

Also Read: ACC misses Street estimates to report net loss of Rs 87.3 crore as elevated costs hurt

Margin, meanwhile, declined 920 basis points year-on-year to 13.4 percent, pretty much in line with expectations, following an increase in the cost of raw materials including fly ash, slag and gypsum.

Analysts had expected margins to be impacted due to a combination of lower realisations and higher costs, led by higher variable costs per tonne. The cost spike is largely led by power-fuel cost due to a lag in consumption of high-cost inventory, they had said.

Also Read: Shree Cement expects cost pressure to ease only from next year

The cement maker's domestic volumes grew 8.3 percent annually while the consolidated volumes rose 6.7 percent.

According to the earnings report, power and fuel costs went up 70 percent annually to Rs 4,296 crore during the quarter. However, average diesel prices slipped by 5 percent on a sequential basis.

UltraTech Cement's net debt increased to Rs 8,357 crore from Rs 5,561 crore in the previous quarter. The rise is primarily on account of increase in working capital and growth capex.

Following the Q2 result announcement, UltraTech Cement shares were trading 0.33 percent higher at Rs 6362.10 on BSE.

(Edited by : Abhishek Jha)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UPS forecasts 2025 revenue below expectations, shares fall
UPS forecasts 2025 revenue below expectations, shares fall
Jan 30, 2025
(Reuters) - -United Parcel Service ( UPS ) on Thursday forecast 2025 revenue below Wall Street estimates, as gains from cost cuts were offset by customers opting for cheaper, slower ground-based deliveries from more profitable air-based services. Shares of the world's largest package delivery fell more than 5% early in the trading session. It forecast full-year revenue of $89 billion,...
Dow's Q4 Earnings, Net Sales Decline
Dow's Q4 Earnings, Net Sales Decline
Jan 30, 2025
06:14 AM EST, 01/30/2025 (MT Newswires) -- Dow (DOW) said Thursday it broke even in Q4, compared with operating earnings of $0.43 per share a year earlier. Analysts polled by FactSet expected $0.22. Net sales for the quarter ended Dec. 31 was $10.41 billion, down from $10.62 billion a year earlier. Analysts surveyed by FactSet expected $10.51 billion. ...
Cargo Therapeutics to Cut Workforce by 50%, Discontinue Lymphoma Treatment Study -- Shares Down Pre-Bell
Cargo Therapeutics to Cut Workforce by 50%, Discontinue Lymphoma Treatment Study -- Shares Down Pre-Bell
Jan 30, 2025
06:14 AM EST, 01/30/2025 (MT Newswires) -- Cargo Therapeutics ( CRGX ) said Wednesday that it will discontinue the phase 2 study of firicabtagene autoleucel, or firi-cel, for patients with large B-cell lymphoma, and reduce its workforce by about 50% to preserve cash for the development of other product candidates. The company said results from an ad-hoc analysis of the...
Thermo Fisher Scientific's Q4 Adjusted Earnings, Revenue Rise
Thermo Fisher Scientific's Q4 Adjusted Earnings, Revenue Rise
Jan 30, 2025
06:09 AM EST, 01/30/2025 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) reported Q4 adjusted earnings Thursday of $6.10 per diluted share, up from $5.67 a year earlier. Analysts polled by FactSet expected $5.94. Revenue for the quarter ended Dec. 31 was $11.40 billion, compared with $10.89 billion a year earlier. Analysts surveyed by FactSet expected $11.28 billion. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved